CAMBRIDGE, Mass., June 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024. Mr. Butler will present at 9:30 a.m. ET to provide updates on the progress of commercial launch activities for Vafseo® (vadadustat) Tablets.A webcast of the ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, Corporate Communications and IR John Butler - President and Chief Executive Officer Nicholas Grund - Chief Commercial Officer Conference Call Participants Ed Arce - H.C. Wainwright Julian Harrison - BTIG Operator Hello, and welcome to the Akebia's First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mod ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.05 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Akebia Th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share AKBA The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION ...

Exhibit 99.1 Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Akebia to host conference call at 8:00 a.m. ET on May 9 CAMBRIDGE, Mass.—May 9, 2024—Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2024. Akebia is launching Vafseo® (vadadustat) tablets, recently approved by the U.S. Food and Drug A ...

Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 9, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call by phone, please click on this Regi ...

Key PointsAkebia Therapeutics is a biotech specializing in treatments for chronic kidney diseases (CKD).Its lead drug, Vafseo, received FDA approval for treating anemia in adult CKD patients who have at least 3 months of dialysis.Vafseo is an oral tablet that has been approved in 37 countries.5 stocks we like better than Akebia TherapeuticsAkebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for pat ...

CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia's common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price ...

Core Viewpoint - Akebia Therapeutics has received FDA approval for Vafseo (vadadustat) Tablets, a once-daily oral HIF-PH inhibitor for treating anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months, aiming to establish a new oral standard of care for this patient population [1][2][9]. Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, headquartered in Cambridge, Massachusetts, and founded in 2007 [8]. - The company plans to leverage its established commercial team and partnerships, particularly with CSL Vifor, to effectively launch Vafseo in the U.S. [4]. Product Details - Vafseo is indicated for adults with anemia due to CKD who have been on dialysis for a minimum of three months and is now approved in 37 countries [1][9]. - The approval is based on data from the INNO2VATE clinical program and post-marketing safety data from Japan, where Vafseo was launched in August 2020 [2][3]. Market Context - Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to CKD, which can lead to significant healthcare costs and adverse clinical outcomes [3]. - Current treatments primarily involve injectable erythropoiesis-stimulating agents administered at dialysis centers, indicating a need for additional oral therapeutic options [3]. Clinical Significance - The introduction of Vafseo is seen as a promising alternative for managing anemia in CKD patients, potentially improving their quality of life [4]. - The product aims to stimulate endogenous erythropoietin production, thereby increasing hemoglobin and red blood cell levels [9]. Future Plans - Akebia will host a conference call on March 28, 2024, to discuss the approval and launch strategy for Vafseo [6][7].

Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of 11.11%.Over the last four quarte ...